Prognostic properties of the association between the S-100B protein levels and the mean cerebral blood flow velocity in patients diagnosed with severe traumatic brain injury

SEBASTIAN DZIERZĘCKI1,2, MIROSŁAW ZĄBEK1,2, ARTUR ZACZYŃSKI3 and RYSZARD TOMASIUK4

1Department of Neurosurgery, Postgraduate Medical Centre; 2Gamma Knife Centre, Brodno Masovian Hospital, 03-242 Warsaw; 3Clinical Department of Neurosurgery, Central Clinical Hospital of The Ministry of The Interior and Administration, 02-507 Warsaw; 4Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities Radom, 26-600 Radom, Poland

Received August 24, 2021; Accepted December 21, 2021

DOI: 10.3892/br.2022.1541

Correspondence to: Dr Sebastian Dzierzęcki, Gamma Knife Centre, Brodno Masovian Hospital, Kondratowicza 8 Str Building H, 03-242 Warsaw, Poland
E-mail: smd@neurochirurg.pl

Key words: S-100B protein, mean maximum blood velocity, early diagnosis, cerebrospinal injury

Abstract. Craniocerebral injury (CBI) is tissue damage caused by a sudden mechanical force. CBI can result in neurological, neuropsychological and psychiatric dysfunctions. Currently, the severity of CBI is assessed using the Glasgow Coma Scale, brain perfusion pressure measurements, transcranial Doppler tests and biochemical markers. This study aimed to determine the applicability of the S-100B protein levels and the time-averaged mean maximum cerebral blood flow velocity ($V_{\text{mean}}$) as a means of predicting the treatment outcomes of CBI in the first 4 days of hospitalization. The results validated the standard reference ranges previously proposed for the concentration of S-100B (0.05-0.23 µg/l) and the mean of cerebral blood flow velocity (30.9 to 74.1 cm/sec). The following stratification scheme was used to predict the success of treatment: Patients with a Glasgow Outcome Scale (GOS) score ≥4 or GOS <4 were stratified into ‘favorable’ and ‘unfavorable’ groups, respectively. The favorable group showed relatively constant levels of the S-100B protein close to the normal range and exhibited an increase in $V_{\text{mean}}$, but this was still within the normal range. The unfavorable group exhibited a high level of S-100B protein and increased $V_{\text{mean}}$ outside of the normal ranges. The changes in the levels of S-100B in the unfavorable and favorable groups were -0.03 and -0.006 mg/l/h, respectively. Furthermore, the rate of decrease in the $V_{\text{mean}}$ value in the unfavorable and favorable groups were -0.26 and -0.18 cm/sec/h, respectively. This study showed that constant levels of S-100B protein, even slightly above the normal range, associated with an increase in $V_{\text{mean}}$ was indicative of a positive therapeutic outcome. However, additional research is required to obtain the appropriate statistical strength required for clinical practice.

Introduction

Craniocerebral injury (CBI) is a heterogeneous group of non-congenital tissue damages caused by a sudden mechanical force, which results in neurological, neuropsychological and psychiatric dysfunctions (1,2). Currently, CBI is one of the leading causes of death in addition to cardiovascular disease and cancer (3). A histogram of age-related CBI shows a bimodal distribution with the first and second maximums for subjects aged 15 and >75 years old, respectively (4). CBI is more common amongst men than among women, showing a ratio between 1.9:1-2.8:1 (4-8).

Current clinical diagnosis of CBI is based on a number of methods, including the Glasgow Coma Scale (GCS) (9), the measurement of cerebral perfusion pressure, the Transcranial Doppler Test (TCD) and analysis of the levels of biomarkers, allowing quantitative evaluation and treatment monitoring of brain tissue damage (10,11).

Given the importance of precise prognostic methods for the diagnosis and effectiveness of TBI treatment, advances in the
quality of the early diagnosis of CBI are essential. Therefore, the time-related changes in S-100B protein levels and the $V_{\text{mean}}$ as well as the associations between these parameters in patients diagnosed with severe CBI as defined by a GCS score $\leq 8$ were investigated in the present study.

Materials and methods

Study subjects. All experiments and methods were performed following relevant guidelines and regulations (40). The Bioethics Committee of the Postgraduate Education Medical Center (Warsaw, Poland) approved the experimental protocols (approval no. 501-2-1-20-49/04). Informed consent was obtained from all subjects or their guardians, and a parent/legal guardian of subjects under 18 years of age.

The present study included patients with severe CBI (GCS score $\leq 8$) admitted to the Department of Neurosurgery and Trauma of the Nervous System at the Medical Center of Postgraduate Education (Warsaw, Poland).

Sample stratification. The total number of patients included in the study was 60, consisting of 51 patients in the unfavorable group and 9 patients in the favorable group. The mean age $\pm$ standard deviation were 48.41±15.24 years (age range, 19-73 years) and 47.20±16.64 years (age range, 14-75 years) in the unfavorable and favorable groups, respectively.

The GCS score was calculated at admission using an internal encoded GCS calculator (41,42) written in Python (Python Software Foundation; python.org/).

According to the European Consortium of Brain Injury Guidelines, all patients were subjected to the standard diagnostic and therapeutic protocols (43). In patients for whom poor ventilation was suspected, a gasometric examination, using a CDI™ blood parameter monitoring system 500, was performed to optimize pCO$_2$ (range, 30-40 mmHg). Furthermore, hematocrit and hemoglobin levels were maintained at 30-40% and 12-14 g/dl, respectively.

On discharge from the Department of Neurosurgery, the patient's health was evaluated using the traditional Glasgow outcome scale (GOS) (44), which is comprised of the following five categories: 1, death; 2, persistent vegetative state; 3, severe disability; 4, moderate disability; and 5, low disability. For this study, patients with a GOS $\geq 4$ and GOS $< 4$ were classified as ‘favorable’ and ‘unfavorable’, respectively.

The inclusion criteria, based on an analysis of GOS as described above, resulted in a study group of 60 patients (48 men and 12 women). The clinical description of the study group after admission to the hospital according to the GCS and Marshall (MCTC) classification (45) is presented in Fig. 1.

The S-100B protein levels were measured in 5 ml venous blood samples collected from patients upon admission to the hospital. Subsequent blood samples were collected at 24-h intervals for 96 h. After clotting and centrifugation for 10 min at 2,000 x g at 4°C, blood samples were stored for further use at -22°C. The S-100B protein concentration was measured using a Anti-S-100 antibody kit (S1-61; cat. no. sc-53438; Santa Cruz Biotechnology, Inc.) according to the manufacturer's protocol (Liaison Sangtec 100; Sangtec Ltd.). The Sangtec 100 kit uses three different monoclonal antibodies (SMST12, SMSK 25 and SMSK 28) directed against the $\beta$-chains of the S-100B homodimer, and has a wide detection range (0.02-30 µg/l). Protein concentration was measured using a LIAISON analyzer (DiaSorin) calibrated with a freeze-dried Sangtec 100 Cal (Low/High) calibrator. The sensitivity threshold for this test was 0.02 µg/l.

$V_{\text{mean}}$ was measured by subjecting patients to a transcranial Doppler examination using a Medasonic Transpect CDS Doppler (Medasonics, Inc.) in the power motion mode TCD (46,47). First, the arteries of the brain base, accessible through the temporal window, were examined. The middle cerebral arteries on the side of the dominant lesion or on the right side of the extent of the lesion were further analyzed. This examination was performed at 24-h intervals for 96 h after the patient was admitted to the Department of Neurosurgery.

Similar to that for the S-100B protein levels, the reference value for $V_{\text{mean}}$ (<30.9 cm/s) was derived from the study in a group comprising 40 healthy volunteers (22 men and 18 women). The mean age of the reference was 43.4±9.17 years (range, 30-61 years).

Statistical analysis. A Shapiro-Wilk test (48) was used to assess the distribution of the parameters investigated. Parameters exhibited either skewed or normal distribution, and the subsequent analysis used was based on the distribution of the data. Data are presented as the mean ± standard deviation, and the minimum and maximum values. Differences between study groups (favorable vs. unfavorable) at a specific time were assessed by analyzing the bootstrapped difference in the means, in which a sample of 10,000 repeats with replacement was used (49). Differential statistics on continuous outcomes of S-100B protein concentration and $V_{\text{mean}}$ were performed using a one-way aligned rank transform for nonparametric factorial ANOVA (50). The clinical treatment outcome factor encompassed two levels (favorable and unfavorable). Due to the shortcomings of current statistical methods in handling advanced nonparametric statistics, it was decided only to discuss one-way nonparametric factorial ANOVA results.

Given the repeated nature of the data and the mortality of the patients, the data was censored to balance the factorial ANOVA model. Post hoc analysis was performed using the estimated marginal means (emmmeans) procedure. The velocity of time-dependent changes in a specific parameter is defined by the slope (tangent) of a line obtained from connected means at consecutive measurement times. P<0.01 was considered to indicate a statistically significant difference. All analyses were performed in R (51).

Results

This study was carried out using two groups of patients stratified by the GOS score (52) at discharge; patients were classified into either an unfavorable (GOS score $< 4$) and favorable (GOS score $\geq 4$) group. No significant differences in age were found between the groups. Fig. 1 shows a general description of the severity of cranio-trauma in patients assessed using the GOS and MCTC scores (53).

The reference range obtained from a healthy patients reference group consisting of 40 healthy volunteers [22 men and 18 women; 47.0±14.77 (age range, 21-80)] for the S-100B levels used in this study was 0.05-0.23 µg/l. A graphical and
Numerical representation of the changes in S-100B levels is shown in Fig. 2 and Table I. The results showed that the patients in the unfavorable group had higher levels of S-100B than those in the favorable group at all measured time points. No statistically significant time-dependent differences, defined by the lack of an overlay between specific confidence intervals, in S-100B concentrations were found within the unfavorable group. However, a significant decrease in serum S-100B protein levels was found between measurements at 24 vs. 48 h, 24 vs. 72 h and 24 vs. 96 h in the favorable group. The difference in the S-100B decrease velocity between the two groups showed a relative decrease equal to 5.4, with velocities of $V_{S-100B_U} = -0.03 \, \mu g/l/h$ and $V_{S-100B_F} = -0.006 \, \mu g/l/h$ for the unfavorable and favorable groups, respectively.

Cerebral flow impairment was analyzed using $V_{mean}$ levels as a function of hospitalization time. The respective data are presented in Table II and Fig. 3. Analysis showed that the patients in the unfavorable group had a significantly lower $V_{mean}$ value than those in the favorable group. Statistically significant differences in $V_{mean}$ were observed between 24 and 96 h and between 48 and 96 h in the unfavorable group. The relative difference in the $V_{mean}$ increase between the unfavorable and favorable groups was 1.44 ($V_{mean,U} = 0.26 \, cm/sec/h$, $V_{mean,F} = 0.18 \, cm/sec/h$, respectively).

Discussion

Due to the poor prognosis of the treatment outcomes of TBI patients (54-63), rendered by the insufficient discriminatory capacity of the current prognostic indicators, the present study assessed the clinical applicability of S-100B protein levels and the $V_{mean}$ as potential prognostic factors.

Briefly, this study introduced and validated a novel concept for predicting a treatment outcome in patients in a favorable and unfavorable group using an amalgam of physical and biochemical parameters collected during the initial hospitalization stage, encompassing the first 4 days after hospital admission.

Over the past 20 years, studies have focused on patient treatment outcomes following a TBI (64-66). Mercier et al (56) summarized 41 reports on the applicability of correlations between TBI and the S-100B levels in patients with severe TBI for long-term prognosis. However, the report described unfavorable treatment results for increased levels of S-100B protein. The present study improved on predicting treatment outcomes based on a combination of physical and biochemical parameters collected during the initial stage of hospitalization.
The therapeutic outcomes of treatment were validated against the GOS, which was evaluated on the 4th day of hospitalization. Patients with a GOS score $<4$ or GOS score $\geq 4$ were stratified into unfavorable and favorable groups, respectively. The mean age of the study sample was 48.73±16.3 years, which is slightly higher than previously reported (67,68). However, no significant differences were determined were found between the age distribution of the present study and those of Jain et al (67) and Jennett (68) using a Student’s t-test. The mortality rate of the patients in the current study was 26.6%, which is higher than previously reported (69). The reasons for these differences are unknown.

The reference range for the normal concentration of S-100B established in the present study was 0.05‑0.23 µg/l. The lower limit of the reference range was similar to that shown in previous studies. However, the upper limit was twice as high (70). In addition, the upper reference limit obtained in the present study was twice the value reported for patients

| Time, h | Mean, mg/l | Standard deviation | Min, mg/l | Max, mg/l | Number of subjects |
|---------|------------|--------------------|-----------|-----------|--------------------|
| 24      | 4.82       | 4.45               | 0.76      | 19.8      | 51                 |
| 48      | 3.84       | 4.21               | 0.47      | 16.8      | 48                 |
| 72      | 3.39       | 4.04               | 0.38      | 17.83     | 40                 |
| 96      | 2.66       | 3.05               | 0.136     | 16.7      | 37                 |
| Mean    | 3.68       | 3.94               | 0.44      | 17.78     | -                  |

Table I. Changes in S-100B levels stratified by the Glasgow Outcome Scale score on discharge from the Department of Neurosurgery.

A, Unfavorable group

| Time, h | Mean, mg/l | Standard deviation | Min, mg/l | Max, mg/l | Number of subjects |
|---------|------------|--------------------|-----------|-----------|--------------------|
| 24      | 1.01       | 0.29               | 0.71      | 1.6       | 9                  |
| 48      | 0.84       | 0.21               | 0.62      | 1.3       | 9                  |
| 72      | 0.83       | 0.35               | 0.51      | 1.5       | 9                  |
| 96      | 0.61       | 0.24               | 0.39      | 1.1       | 9                  |
| Mean    | 0.82       | 0.27               | 0.56      | 1.38      | -                  |

B, Favorable group

| Time, h | Mean, mg/l | Standard deviation | Min, mg/l | Max, mg/l | Number of subjects |
|---------|------------|--------------------|-----------|-----------|--------------------|
| 24      | 32.06      | 11.31              | 5         | 67        | 51                 |
| 48      | 39.73      | 16.53              | 6         | 75        | 48                 |
| 72      | 38.78      | 20.77              | 5         | 120       | 40                 |
| 96      | 45.43      | 25.1               | 6         | 145       | 37                 |
| Mean    | 39.00      | 18.43              | 5.50      | 101.75    | -                  |

Table II. Changes in time-averaged mean maximum cerebral blood flow velocity stratified by Glasgow Outcome Scale score on discharge from the Department of Neurosurgery.

A, Unfavorable group

| Time, h | Mean, mg/l | Standard deviation | Min, mg/l | Max, mg/l | Number of subjects |
|---------|------------|--------------------|-----------|-----------|--------------------|
| 24      | 41.78      | 7.17               | 32        | 56        | 9                  |
| 48      | 51.56      | 15.53              | 36        | 87        | 9                  |
| 72      | 52         | 11.43              | 39        | 75        | 9                  |
| 96      | 60.38      | 14.99              | 44        | 91        | 9                  |
| Mean    | 51.43      | 12.28              | 37.75     | 77.25     | -                  |

B, Favorable group
with an isolated head injury for whom CT scans for mild TBI were negative (71,72). Furthermore, an apparent discrepancy was found between the pathological levels of S-100B reported in this study (>0.235 µg/l) and those of a previous study (>0.5 µg/l) (73).

The present study is amongst only a few to report the association between time-dependent changes in S-100B levels and the outcome of TBI treatment (74-76). A striking discrepancy was observed between the data in the present study and those reported by Gyorgy et al (74), where it was previously shown that there was no correlation between the severity of TBI and serum S-100B levels. Additionally, the study by Gyorgy et al (74) also showed an increase in the S-100B levels between 7-72 h after injury, whereas the current study showed a pronounced decrease in the S-100B levels. However, a comparison of the results of this study with those reported by Shakeri et al (16), revealed a lack of statistical differences between S-100B protein levels stratified into favorable and unfavorable groups in both studies. The observed difference between this and the latter study may be due to different analytic techniques, such as the use of monoclonal antibodies in the present study and ELISA in the ins the study by Gyorgy et al (74). Furthermore, the present study employed advanced techniques for the analysis of nonparametric data, such as one-way aligned rank transformation for nonparametric factorial ANOVA and bootstrap analysis. Such an approach allowed for identification of the subtle differences between S-100B levels and the mean cerebral blood flow velocity between the favorable and unfavorable outcome groups.

The results of the present study agree with a report by Raabe and Seifert (73), which indicated that serum levels of S-100B were significantly higher in patients with unfavorable outcomes than in those with favorable outcomes. In patients with favorable outcomes, high initial levels of S-100B returned to normal levels within 96 h. Furthermore, both studies revealed a noticeable difference in serum S-100B levels between the unfavorable and favorable groups, with an apparent decrease in S-100B levels within 3-4 days after hospitalization. The present study also revealed a decrease in S-100B concentration velocity of 0.03 µg/l/h in the unfavorable group. This result shows that patients in the unfavorable group require 153 h (6.3 days) to reach the normal reference range.

Compared to Raabe and Seifert (73), the present study showed that the increase in S-100B protein levels observed in the favorable group did not return to normal, and was on average equal to 0.61 mg/l on day 4, remaining at levels around three times higher than the standard reference value (0.23 µg/l) and 12 times the value reported by Raabe and Seifert (73). Furthermore, the velocity of the decrease in serum S-100B concentration in the favorable group was 0.006 µg/l/h, indicating that a favorable patient would need 130 h of hospitalization before reaching the S-100B standard reference range. This observation may indicate that the difference in 30 h between the unfavorable and favorable groups in reaching the standard S-100B reference range is crucial for patient recovery. The lack of changes can lead to irreversible neuronal dysfunction with a consequent increase in extracellular calcium levels and the activation of toxic nitric oxide (77,78). Thus, the extended time required to recover S-100B levels may be a primary cause of increased mortality. Comparison of this study with a meta-analysis of 39 studies on a total of 1,862 patients (56) confirmed the results presented in the present study. That is, S-100B serum levels in the unfavorable group in the range of 2.16-14.0 µg/l.

The results of the present study also corroborate with those of previous studies (79-82), which showed that the initial concentration of S-100B is of paramount importance for the prediction of the outcome of TBI. In addition, the present study also substantiated the previous findings relating to the clinical significance of S-100B levels up to 3 days after hospital admission (83-89).

Cerebral flow dynamics determined by TCD examination has been one of the most popular neurosurgical diagnostic tools since the 1980s (90,91). This technique allows for analysis of abnormalities in cerebral circulation in patients with cranio-cerebral trauma (91-95). The impairment of cerebral flow reflected in Vmean is of paramount importance for determining the treatment outcomes of patients with severe cranio-cerebral trauma (96,97). In the present study, an abnormal Vmean level was defined by values <30.9 cm/s, which is in agreement with previous reports (39,98).

The present study showed that in the successful group, the majority of the patients exhibited a Vmean >30.9 cm/s (the threshold value defining the healthy subjects) during the first 24 h of hospitalization. However, in the unfavorable group, the number of patients with Vmean >30.9 cm/s was notably lower. This observation indicates the direct applicability of Vmean for predicting treatment outcomes amongst patients with severe CBI.

The velocity of the increase in Vmean in the unfavorable group was Vmean, V=0.26 cm/sec/h. This value was significantly lower than those previously reported (99,100) showing an adverse outcome for the following cases: An increase in Vmean equivalent to 2.08 cm/sec/h during the first 24 h (99) and Vmean equivalent to 2.7 cm/sec/h after 3 days of hospitalization (100). This observation indicates that the velocity of changes in Vmean may have a prognostic value in the clinical setting. However,
due to the discrepancy between the previous (99,100) and this report, further studies are required.

Analysis of the relationship between the parameters that define the unfavorable treatment outcomes led to the following observations. A significant time-dependent decrease in S-100B levels (a negative velocity equivalent to 0.03 μg/l/h) was associated with a statistically significant increase in V_{mean} levels (a positive velocity of 0.26 cm/sec/h). A favorable outcome was defined by the lack of changes in S-100B levels and a time-dependent increase in V_{mean} with a velocity of 0.18 cm/sec/h.

In conclusion, the present study is the first to report on the associations between S-100B protein levels and V_{mean} to predict patient treatment outcomes in those who have suffered a TBI or CBI, to the best of our knowledge. It was established that within the first 4 days of hospitalization, a constant level of S-100B protein even slightly above the normal range, associated with an increase in V_{mean} was a predictor of successful treatment outcomes. Moreover, following the conclusion of the study by Thelin et al. (22), which suggested that S100B could be used as a versatile screening, monitoring and prediction tool in the management of TBI patients, the present study revealed that serum concentration of S100B itself was of limited use in predicting TBI outcomes. However, additional studies are required to validate this observation and to obtain the appropriate statistical power. Moreover, the limited clinical applicability of currently studied CBI markers indicates the need for the continuous search for other markers, which exhibit improved specificity and sensitivity in a clinical environment.

Acknowledgements

Not applicable.

Funding

The research reported in this publication was supported by the Commission for Scientific Research of the Medical Center for Postgraduate Education in Warsaw Research (grant no. 501-2-1-20-49/04).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

SD collected and analyzed the data. SD, MZ, AZ and RT collected the data and wrote the manuscript. RT analyzed the data. All authors have read and approved the final manuscript. SD, RT and MZ have seen and confirmed the authenticity of the raw data.

Ethics approval and consent to participate

The Bioethics Committee of the Postgraduate Education Medical Center in Warsaw (Poland) approved the experimental protocols (approval no. 501-2-1-20-49/04). Informed consent was obtained from all subjects or their guardians and a parent/legal guardian of subjects under 18 years of age.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Seletz E: Craniocebral injuries. Calif Med 84: 292-294, 1956.
2. Romodanov AP and Pedachenko EG: Features of the clinical manifestation of contusion of the cerebral hemisphere in patients with hypertension. Zh Vopr Neirokhir Im N N Burdenko 3: 3-6, 1983 (In Russian).
3. Dewan MC, Rattani A, Gupta S, Batculon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, SHRIME MG, Rubiano AM, et al: Estimating the global incidence of traumatic brain injury. J Neurosurg: April 1, 2018 (Epub ahead of print). doi: 10.3171/2017.10.JNS17352.
4. Toccalino D, Colantonio A and Chan V: Update on the epidemiology of work-related traumatic brain injury: A systematic review and meta-analysis. Occup Environ Med 78: 769-776 2021.
5. Lasry O, Liu EY, Powell GA, Ruel-Laliberte J, Marcoux J and Buckeridge DL: Epidemiology of recurrent traumatic brain injury in the general population: A systematic review. Neurology 89: 2198-2209, 2017.
6. Bruns J Jr and Hauser WA: The epidemiology of traumatic brain injury: A review. Epilepsia 44: 2-10, 2003.
7. Masson F, Thicoine M, Aye P, Mokni T, Senjean P, Schmitt V, Dessalles PH, Cazaugade M and Labadens P: Aquitaine Group for Severe Brain Injuries Study: epidemiology of severe brain injuries: A prospective population-based study. J Trauma 51: 481-489, 2001.
8. Maegle M, Engel D, Bouillon B, Lefering R, Fach H, Raum M, Buchleister B, Schaefer U, Klug N and Neugebauer E: Incidence and outcome of traumatic brain injury in an urban area in Western Europe over 10 years. Eur Surg Res 39: 372-379, 2007.
9. Teasdale G and Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet 2: 81-84, 1974.
10. Dadas A, Washington J, Diaz-Arrastia R and Janigro D: Biomarkers in traumatic brain injury (TBI): A review. Neuropsychiatr Dis Treat 14: 2989-3000, 2018.
11. Gan ZS, Stein SC, Swanson R, Guan S, Garcia L, Mehta D and Smith DH: Blood biomarkers for traumatic brain injury: A quantitative assessment of diagnostic and prognostic accuracy. Front Neurol 10: 446, 2019.
12. Korfias S, Stranjalis G, Papadimitriou P, Psachoulia C, Daskalakis G, Antsaklis A and Sakas DE: Serum S-100B protein as a biochemical marker of brain injury: A review of current concepts. Curr Med Chem 13: 3719-3731, 2006.
13. Harris A, Keuler S, Kerska A and Rogatzki M: Serum protein S100B, a biomarker for head injury or skeletal muscle damage? FEBS J 3: 2123-2123, 2017.
14. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemelä O and Hillbom M: Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 56: 1229-1234, 2004.
15. Rodríguez-Rodríguez A, Egea-Guerrero JJ, Gordillo-Escobar E, Enamorado-Enamorado J, Hernández-García C, Ruiz de Azaúa-López Z, Vilches-Arenas A, Guerrero JM and Murillo-Cabezas F: S100B and Neuron-specific Enolase as mortality predictors in patients with severe traumatic brain injury. Neurrol Res 38: 130-137, 2016.
16. Shakeri M, Mahdkhah A and Panahi F: S100B protein as a Post-traumatic biomarker for prediction of brain death in association with patient outcomes. Arch Trauma Res 2: 76-80, 2013.
17. Pförtmueller CA, Drexel C, Krähenmann-Müller S, Leichtle AB, Fiedler GM, Lindner G and Exadaktylos AK: S-100 B Concentrations are a predictor of decreased survival in patients with major trauma, independently of head injury. PLoS One 11: e0152822, 2016.
18. Rodríguez-Rodríguez A, Egea-Guerrero JJ, León-Justel A, Gordillo-Escobar E, Revuelto-Rey J, Víches-Arenas A, Carrillo-Vico A, Domínguez-Roldán JM, Murillo-Cabezás F and Pérez-Agüayo M: Differentiation of the S100B protein from urine and serum as an early predictor of mortality after severe traumatic brain injury in adults. Clin Chim Acta 414: 228-233, 2012.

19. Duda I, Krzyczk L, Jędreżyk-Szypułka H and Lewin-Kowalik J: Serum levels of the S100B protein and neuron-specific enolase are associated with mortality in critically ill patients. Acta Biochim Pol 64: 647-652, 2017.

20. Olivercrona M, Rodling-Wahlström M, Naredi S and Koskinen LO: S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 80: 1241-1247, 2009.

21. Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP and Wagner AK: S100B as a Prognostic biomarker in outcome prediction for patients with severe traumatic brain injury. J Neurotrauma 30: 946-957, 2013.

22. Thelin EP, Nelson DW and Bellander BM: A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien) 159: 209-225, 2017.

23. Beyer H, Biberthaler P and Bogner-Flatz V: Chapter 10-S100 proteins: Evolution and functions. In: Calcium and S100B regulation of p53-dependent cell growth arrest and apoptosis, Mol Cell Biol 18: 4272-4281, 1998.

24. Telegér C and Ratanakorn D: Physics and principles. In: Transcranial Doppler Ultrasonography, Babikian V and Wechsler L (eds), Butterworth-Heinemann, Waltham, MA, pp3-11, 1999.

25. Rhee C, Brain Doppler: Principles and Applications. In: Transcranial Doppler Ultrasonography, Babikian V and Wechsler L (eds), Butterworth-Heinemann, Waltham, MA, pp3-11, 1999.

26. World Medical Association: World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310: 2191-2194, 2013.

27. Murray GD, Butcher I, McHugh GS, Lu J, Mushkudiani NA, Maas AI, Marmarou A and Steyerberg EW: Multivariable prognostic analysis in traumatic brain injury: Results from the IMPACT study. J Neurotrauma 24: 329-337, 2007.

28. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, McHugh GS, Murray GD, Marmarou A, Roberts I, Habbema JD and Maas AI: Predicting outcome after traumatic brain injury: Development and international validation of prognostic scores based on admission characteristics. PLoS Med 5: e165, 2008.

29. Maas AI, Dearden M, Teasdale GM, Braakman R, Cohodon F, Iannotti F, Karimi A, Lapierre F, Murray G, Ohman J, et al: EBIC-guidelines for management of severe head injury in adults. European brain injury consortium. Acta Neurochir (Wien) 139: 286-294, 1997.

30. Salolitto K, Carrick M, Stewart Levy A, Morgan BC, Slone DS and Bar-Or D: The epidemiology, prognosis, and trends of severe traumatic brain injury with presenting Glasgow Coma Scale of 3. J Crit Care 38: 197-201, 2017.

31. Mahadewa TGB, Golden N, Saputra A and Ryalino C: Modified revised Trauma-Marshall score as a proposed tool in predicting the outcome of moderate and severe traumatic brain injury. Open Access Emerg Med 10: 135-139, 2018.

32. Naqvi Y, Yap KH, Ahmad G and Ghosh J: Transcranial Doppler ultrasound: A review of the physical principles and major applications in critical care. J Crit Care Emerg Surg 9: 105‑113, 2020.

33. Rodríguez A, Cervera E, Macchia G, Mendoza X, Martínez W, Pérez M, Sanjuán H and Villalba H: Utility of S100B as a potential tool for Neuromonitoring and prediction of neuroworsening in acute phase of traumatic brain injury. Panam J Trauma Care Emerg Surg 9: 105‑113, 2020.

34. Czeteier A, Amrein K, Gravesteijn BY, Coste S, Richert A and Wechsler L: Development and international validation of prognostic scores for patients with severe traumatic brain injury. J Neurosurg 129: 227‑233, 2018.

35. Kim HJ, Tsao JW and Stanfill AG: The current state of biomarkers for Traumatic Brain Injury. Wu AHB and Peacock WF (eds). Transcranial Doppler ultrasound goal-directed therapy for the early management of severe traumatic brain injury. Int J Vasc Med 2013: 629378, 2013.
60. Myburgh JA, Cooper DJ, Finfer SR, Venkatesh B, Jones D, Higgins A, Bishop N and Higlett T: Australasian Traumatic Brain Injury Study (ATBIS) Investigators for the Australasian New Zealand Intensive Care Society Critical Care Trauma Group: Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand. J Trauma 64: 854-862, 2008.

61. Thornhill S, Teasdale GM, Murray GD, McEwen J, Roy CW and Penny KJ: Disability in young people and adults one year after head injury: Prospective cohort study. BMJ 320: 1631-1635, 2000.

62. Xydaikis MS, Ling GS, Mulligan LP, Olsen CH and Dorlac WC: Epidemiologic aspects of traumatic brain injury in acute combat casualties at a major military medical center: A cohort study. Ann Neurol 72: 673-681, 2012.

63. Kraus JF and McArthur DL: Epidemiologic aspects of brain injury. Neurol Clin 14: 435-450, 1996.

64. Mamelak AN, Pitts LH and Damron S: Predicting survival from head trauma 24 hours after injury: A practical method with therapeutic implications. J Trauma 41: 99-99, 1996.

65. Lieberman JD, Pasqualet MD, Gaciu R, Cipolle MD, Mark Li P and Wasser TE: Use of admission Glasgow Coma Score, pupil size, and pupil reactivity to determine outcome for trauma patients. J Trauma 55: 437-443, 2003.

66. Combes P, Fauvage B, Colonna M, Passagia JG, Chirossel JP and Jacquot C: Severe head injuries: An outcome prediction and survival analysis. Crit Care Med 22: 1391-1395, 1996.

67. Jain S, Dharap SB and Gore MA: Early prediction of outcome in very severe closed head injury. Injury 39: 598-603, 2008.

68. Jennett B: Epidemiology of head injury. J Neurol Neurosurg Psychiatry 60: 362-369, 1996.

69. Gerber LM, Cusco YL, Carney N, Hartl R and Ghajar J: Marked reduction in mortality in patients with severe traumatic brain injury. J Neurosurg 119: 1583-1590, 2013.

70. Wiesmann M, Missler U, Gottmann D and Gehring S: Plasma S‑100b protein concentration in healthy adults is age‑ and sex‑independent. Clin Chem 44: 1056-1058, 1998.

71. Biberthaler P, Mussack T, Wiedemann E, Kanz KG, Koelsch M, Wiesmann M, Missler U, Gottmann D and Gehring S: Plasma protein S-100B as a serum marker of brain damage in severe head injury: Preliminary results. Neurosurgery 27: 106‑112, 1990.

72. Chan KH, Dearden NM and Miller JD: Transcranial Doppler ultrasonography for the management of severe traumatic brain injury. J Intensive Care 4: 29‑29, 2016.

73. Pyo H, Bateman RM, Tzourio‑Mazoyer N, Giedd JN, Toga AW, Gadian DG, Sowell ER, Jernigan TL, Evans AC and Miller KD: Brain morphometry in chronic traumatic encephalopathy: Voxel‑based morphometry using subcortical and cortical brain masks. Neuroimage 62: 766‑773, 2012.

74. Tsivgoulis G, Alexander AV and Sloan MA: Advances in transcerebral Doppler ultrasonography. Curr Neurol Neurosci Rep 9: 46-54, 2009.

75. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.